HM 17321
Alternative Names: HM-17321Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator Hanmi Pharmaceutical
- Class Obesity therapies
- Mechanism of Action Corticotropin releasing factor receptor 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 06 Nov 2024 HM 17321 is available for licensing as of 06 Nov 2024. https://www.hanmipharm.com/science/pipeline/innovative-snapshot-pipeline.hm
- 06 Nov 2024 Preclinical trials in Obesity in South Korea (unspecified route)
- 06 Nov 2024 Pharmacodynamics data from preclinical trial in Obesity released by Hanmi Pharm